1:42 PM
Sep 06, 2018
 |  BC Extra  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of patients with chronic HBV infection. The biotech added $465 million in market cap on the data.

The data were from eight patients that received three monthly subcutaneous doses of ARO-HBV in the lowest two dose cohorts of the Phase I/II AROHBV1001 study. The cohorts included both...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >